A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
Phase 2
Not yet recruiting
- Conditions
- Parkinson Disease
- Interventions
- Drug: VutiglabridinDrug: Placebo
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Glaceum
- Target Recruit Count
- 90
- Registration Number
- NCT06329141
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HGR4113 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: HGR4113Drug: Placebo
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Glaceum
- Target Recruit Count
- 40
- Registration Number
- NCT05642377
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses
Phase 1
Completed
- Conditions
- Obesity
- Interventions
- Drug: PlaceboDrug: HSG4112
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Glaceum
- Target Recruit Count
- 36
- Registration Number
- NCT05310032
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients
Phase 2
Completed
- Conditions
- Obesity
- Interventions
- Drug: HSG4112Drug: Placebo
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Glaceum
- Target Recruit Count
- 81
- Registration Number
- NCT05197556
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112
Phase 1
Completed
- Conditions
- Obesity
- Interventions
- Drug: HSG4112
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Glaceum
- Target Recruit Count
- 12
- Registration Number
- NCT04733001
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112
Phase 1
Completed
- Conditions
- Obesity
- Interventions
- Drug: PlaceboDrug: HSG4112
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Glaceum
- Target Recruit Count
- 90
- Registration Number
- NCT04732988
- Locations
- π°π·
Kyungpook National University Hospital, Daegu, Korea, Republic of
π°π·Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112
Phase 1
Completed
- Conditions
- Obesity
- Interventions
- Drug: HSG4112Drug: Placebo
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Glaceum
- Target Recruit Count
- 40
- Registration Number
- NCT04703764
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
π°π·Kyungpook National University Hospital, Daegu, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath